Phathom Pharmaceuticals Set to Showcase VOQUEZNA at ACG 2025
Phathom Pharmaceuticals' Participation at ACG 2025
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT), a leading biopharmaceutical entity specializing in innovative therapies for gastrointestinal ailments, proudly announces its active involvement in the upcoming American College of Gastroenterology's (ACG) 2025 Annual Scientific Meeting. This significant event is scheduled to take place in Phoenix with a series of engagements focused on enhancing education and awareness around gastrointestinal diseases.
Engagements at the ACG Meeting
At the ACG 2025, Phathom will prominently exhibit its advancements and share insights directly with healthcare professionals and the scientific community. One of the highlight sessions will include a product theater focused on VOQUEZNA (vonoprazan), recognized for its efficacy in treating Gastroesophageal Reflux Disease (GERD).
CEO Remarks
Steve Basta, President and CEO of Phathom, expressed enthusiasm about expanding the recognition of VOQUEZNA within the GERD treatment community. He stated, "Participating in events like ACG allows us to connect with medical professionals, share valuable clinical experiences, and reinforce our dedication to improving patient health outcomes in gastrointestinal care."
Phathom's Activities Schedule at ACG 2025
Below is an overview of Phathom's planned activities during the conference:
Exhibit Participation
From October 26 to October 29, 2025, Phathom's Medical Affairs and Commercial teams will be available for discussions at booth #214. Attendees are encouraged to visit and learn more about the latest developments in GI treatments.
Product Theater Session
On October 27, 2025, Phathom will host a product theater session titled "VOQUEZNA (vonoprazan) Product Theater – Expert Insights on GERD Therapy: A Case-Based Approach with a First-in-Class Acid Suppressant." This insightful session will feature expert Dr. John Erik Pandolfino, an esteemed figure in the field.
About VOQUEZNA
VOQUEZNA (vonoprazan) is classified as a potassium-competitive acid blocker (PCAB) and serves as a critical option for adults dealing with GERD. It is approved for:
- Healing all grades of Erosive Esophagitis (Erosive GERD) and providing relief from heartburn related to this condition.
- Maintaining healing of Erosive GERD and alleviating associated heartburn.
- Offering relief for patients suffering from Non-Erosive GERD.
Safety Information and Precautions
While VOQUEZNA provides significant benefits, like all medications, it carries potential risks. Notably:
- It is contraindicated in individuals hypersensitive to its components or concurrently using certain medications.
- Patients experiencing suboptimal responses may require further diagnostic testing to rule out underlying issues.
- Monitoring for rare but serious adverse reactions, such as acute tubulointerstitial nephritis, is advised.
Phathom's Commitment to Patient Health
Phathom Pharmaceuticals' mission revolves around delivering innovative solutions for GI disorders. With its focus on education and patient engagement at prominent scientific gatherings like ACG, Phathom is committed to ensuring the continued development and support of effective treatments for diseases like GERD.
Contact Information
For inquiries regarding Phathom Pharmaceuticals or its products, please reach out to: Nick Benedetto at 1-877-742-8466 or email media@phathompharma.com. For investor questions, contact Eric Sciorilli at the same telephone number or email ir@phathompharma.com.
Frequently Asked Questions
What is VOQUEZNA used for?
VOQUEZNA is used for treating Erosive and Non-Erosive Gastroesophageal Reflux Disease (GERD).
When is the ACG 2025 Annual Scientific Meeting?
The meeting will be held from October 24 to 29, 2025.
Who is presenting at the VOQUEZNA product theater?
Dr. John Erik Pandolfino will present expert insights during the product theater session.
Where can I learn more about Phathom Pharmaceuticals?
Visit Phathom's website at www.phathompharma.com for more information.
How can I report an adverse reaction?
Adverse reactions can be reported by calling Phathom at 1-888-775-PHAT or the FDA at 1-800-FDA-1088.
About The Author
Contact Dominic Sanders privately here. Or send an email with ATTN: Dominic Sanders as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.